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Abstract
Background Living tissues maintain a fine balance between protein synthesis and protein breakdown rates. Animal studies
indicate that protein synthesis rates are higher in organs when compared with skeletal muscle tissue. As such, organ and
tumour protein synthesis could have major effects on whole-body protein metabolism in wasting disorders such as cancer
cachexia. We aimed to assess protein synthesis rates in pancreatic tumour tissue and healthy pancreas, liver, and skeletal
muscle tissue in vivo in humans.
Methods In eight patients with pancreatic cancer undergoing pancreaticoduodenectomy, primed continuous infusions with
L-[ring-13C6]phenylalanine and L-[3,5-
2H2]tyrosine were started prior to surgery and continued throughout the surgical procedures.
During surgery, plasma samples and biopsies from the pancreas, pancreatic tumour, liver, and vastus lateralis muscle were taken.
Post-absorptive fractional protein synthesis rates were determined bymeasuring incorporation of labelled L-[ring-13C6]phenylalanine
in tissue protein using the weighed plasma L-[ring-13C6]phenylalanine enrichments as the precursor pool.
Results Five male patients and three female patients with a mean age of 67 ± 2 years were included into this study. Plasma
L-[ring-13C6]phenylalanine enrichments (6–9mole per cent excess) did not change during surgery (P = 0.60). Pancreatic tumour
protein synthesis rates were 2.6-fold lower than surrounding pancreatic tissue protein synthesis rates (0.268 ± 0.053 vs.
0.694 ± 0.228%/h, respectively; P = 0.028) and 1.7-fold lower than liver protein synthesis rates (0.268 ± 0.053 vs.
0.448 ± 0.043%/h, respectively; P = 0.046). Among healthy organ samples, protein synthesis rates were 20-fold and 13-fold
higher in pancreas and liver, respectively, compared with skeletal muscle tissue (0.694 ± 0.228 and 0.448 ± 0.043 vs.
0.035 ± 0.005%/h, respectively; P < 0.05).
Conclusions Liver and pancreas tissue protein synthesis rates are higher when compared with pancreatic tumour and skeletal
muscle tissue protein synthesis rates and can, therefore, strongly impact whole-body protein metabolism in vivo in humans.
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Background
All tissues are in a constant state of turnover, with a tightly
controlled regulation of tissue protein synthesis and protein
breakdown rates.1 Because of the relative ease of sampling
skeletal muscle tissue,2 ample information is available on the
synthesis rates (average 1–2% per day3) and factors influenc-
ing skeletal muscle protein synthesis in humans. Prior work
in animals suggests that protein synthesis rates in organ tissue
are much higher compared with skeletal muscle tissue protein
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synthesis rates.1,4 This likely applies to humans as well, and
because ~40% of total human protein content is stored in
non-muscle tissue,5 it suggests that protein synthesis in organs
could play a significant role in whole-body proteinmetabolism.
In addition, protein synthesis rates in tumours contribute to
whole-body protein metabolism as indicated by data from rats
bearing hepatomas and sarcomas.6 These observations
suggest that tumour protein synthesis might be a potential
driver of wasting diseases such as cancer cachexia and calls
for human studies of protein synthesis rates in tumour tissue
relative to surrounding healthy organs and skeletal muscle.
In the present study, we applied contemporary stable
isotope methodology using primed continuous intravenous
L-[ring-13C6]phenylalanine infusions prior to and during
pancreaticoduodenectomy in eight patients with pancreatic
cancer. During the surgical procedures (5–7 h), biopsies were
taken from the pancreatic tumour as well as healthy
pancreas, vastus lateralis muscle, and liver tissue, allowing




Eight consenting patients with cancer of the pancreatic head
undergoing surgery were enrolled in this study (Table 1).
Inclusion criteria were (i) age ≥18 years, (ii)
pancreaticoduodenectomy for suspected adenocarcinoma of
the pancreas head, and (iii) presence of cachexia [weight loss
>5% in the last 6 months; weight loss >2% and body mass
index <20; or weight loss >2% and sarcopenia (L3-skeletal
muscle index of <55 cm2/m2 for men and <39 cm2/m2 for
women)].7 Patients were excluded from participation if they
met any of the following criteria: active acute pancreatitis,
chronic pancreatitis, previous pancreatic surgery, inflamma-
tory bowel disease, use of systemic steroids in the past
4 weeks, abdominal surgery in the past 4 weeks, phenylke-
tonuria, insulin-dependent diabetes mellitus, global initiative
for chronic obstructive lung disease III or IV, heart failure,
receiving total parenteral nutrition at day of surgery,
pregnancy, neoadjuvant chemotherapy, or radiotherapy. Pa-
tients on systemic steroid use were excluded as it can induce
muscle atrophy through the ubiquitin proteasome pathway
and inhibit insulin and insulin-like growth factor 1 mediated
protein synthesis.8 In rats, the inhibiting effect on the skeletal
muscle fractional synthetic rate (FSR) is restored to normal
3 days after steroid administration.9 Therefore, we found a
period of 4 weeks without systemic steroid use before
surgery to be appropriate. Patients were included consecu-
tively at the Department of Surgery of the Maastricht Univer-
sity Medical Centre. Nutritional status was assessed by a
trained physician in the outpatient department and included
measurements of weight and height, patient-reported weight
loss in the last 6 months, triceps skinfold thickness, handgrip
strength, patient-generated subjective global assessment,
and malnutrition universal screening tool. Systemic inflamma-
tion was assessed by measuring plasma C-reactive protein
(CRP) and albumin levels preoperatively (routine in-hospital
laboratory test) and by measuring preoperative levels of in-
terleukin (IL)-1β, IL-6, and tumour necrosis factor-α (TNF-α)
by enzyme-linked immunosorbent assay. Preoperative muscle
mass was measured using computed tomography imaging on
the third lumbar vertebra and sliceOmatic (Tomovision,
Magog, Canada), which is a reliable method for assessing
total body skeletal muscle mass.10
Study protocol
Patients were admitted to the hospital 1 day prior to
surgery. Two hours before surgery, a venous blood sample
was taken (t = 0). Thereafter, a primed continuous intrave-
nous infusion of L-[ring-13C6]phenylalanine and L-[3,5-
2H2]
tyrosine was started and continued throughout surgery
(5–7 h). Before surgery, a catheter was placed in the radial
artery from which arterial blood samples were drawn every
15–30 min. Following the start of surgery, the first biopsies
of the liver and vastus lateralis muscle were taken (t = 1).
During surgery, the surgeon judged the feasibility to
perform a resection of the tumour [pylorus-preserving
Table 1 Patient characteristics
Patients (n = 8)
Age (years) 67 ± 2
Female (n, %) 3, 37.5%
Male (n, %) 5, 62.5%
BMI (kg/m2) 24.3 ± 1.4
Weight loss over the last 6 months (%) 13.0 ± 2.2
L3-skeletal muscle index (cm2/m2) 45.1 ± 2.5
L3-visceral adipose tissue index (cm2/m2) 58.1 ± 16.7
L3-subcutaneous adipose tissue index (cm2/m2) 57.3 ± 11.5
Type of surgery (n, %)
Pylorus-preserving pancreaticoduodenectomy 6, 75%
Double bypass 2, 25%
Histopathological diagnosis (n, %)
Pancreatic adenocarcinoma 5, 62.5%
Ampullary carcinoma 1, 12.5%
Intrapancreatic cholangiocarcinoma 2, 25%
PG-SGA score 15.4 ± 2.0
MUST score 1.8 ± 0.2
Triceps skinfold (mm) 12.8 ± 1.7
Handgrip strength (kg) 30.4 ± 2.4
C-reactive protein (mg/L) 5.9 ± 1.3
Albumin (g/L) 30.7 ± 1.3
Interleukin-1β (pg/mL) 5.1 ± 0.8
Interleukin-6 (pg/mL) 13.1 ± 9.1
TNF-α (pg/mL) Not detecteda
Data are presented as mean ± standard error of the mean. BMI,
body mass index; MUST, malnutrition universal screening tool;
PG-SGA, patient generated selective global assessment; TNF-α, tu-
mour necrosis factor-α.
aPlasma concentrations <2 pg/mL for all patients.
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pancreaticoduodenectomy (PPPD)] or alternatively palliative
surgery in which the pancreas remains untouched (double
bypass). At t = 2 (just before the blood supply to the
tumour containing pancreas head was interrupted),
repeated biopsies of the liver and vastus lateralis muscle,
and from the non-tumorous pancreas, were collected.
Muscle biopsy samples from the vastus lateralis were taken
from the same incision; the first sample was taken from
different fibres (3 cm distal of the incision with the biopsy
needle pointing inwards) from the second (3 cm proximal
of the incision with the biopsy needle pointing outwards).
A schematic overview of the study protocol is shown in
Figure 1. The study protocol was reviewed and approved
by the medical ethics committee of the Maastricht
University Medical Centre (No: NL45969.068.13).
Biopsy and plasma analyses
The PPPD specimen was transferred to the pathology labora-
tory immediately after resection, where the pathologist iden-
tified the tumour macroscopically and provided a fresh
approximately 5 mm tumour containing tissue slice. Samples
were taken within 15 min after removal from the body.
Frozen sections were cut and thereafter stained with
haematoxylin and eosin for histologic examination. A pathol-
ogist specialized in pancreas pathology examined all tumour
biopsies using light microscopy to confirm the presence of
malignant cells in the biopsies, which is considered to be
the gold standard for diagnosing malignancies of the
pancreas.11 None of the pancreatic tumours showed signs
of necrosis or ischaemia on histologic examination.
Figure 1 Schematic overview of the study protocol. Patients received a primed continuous infusion of L-[ring-13C6]phenylalanine and L-[3,5-
2H2]tyro-
sine before and during surgery. Arterial plasma samples were drawn every 15–30 min. At t = 1 (~4 h after start of infusion), muscle and liver biopsies
were obtained. At t = 2 (~6.5 h after start of infusion), muscle, liver, pancreas, and pancreatic tumour biopsies were obtained.
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Biopsies from healthy pancreas, liver, and skeletal muscle
were cleaned of any visible blood and immediately frozen in
liquid nitrogen in the operating theatre and stored at
80°C until analysis. Fifty milligrams of tissue were freeze-
dried and homogenized in ice-cold 2% perchloric acid with a
sonicator and subsequently centrifuged at 1000 g at 4°C.
The supernatant was separated from the protein pellet for
assessment of tissue-free phenylalanine enrichments.
Blood was collected in EDTA tubes pre-chilled on ice and
centrifuged at 1000 g at 4°C for 5 min. Plasma aliquots were
frozen in liquid nitrogen and stored at 80°C until analysis.
Plasma IL-1β, IL-6, and TNF-α concentrations were measured
by enzyme-linked immunosorbent assays according to the
manufacturer’s instructions (U-CyTech Biosciences, Utrecht,
the Netherlands; assays CT576-10, CT744-10, and CT747-10,
respectively). Plasma proteins were extracted by adding
ice-cold 2% perchloric acid up to a concentration of 2% and
subsequently centrifuged at 1000 g at 4°C.
For plasma and tissue supernatants, phenylalanine was
derivatized to its t-butyldimethyl-silyl derivative, and its 13C
enrichment was determined in duplicates by electron impact
ionization gas chromatography mass spectrometry (model
6890N GC/5973N MSD; Agilent, Little Falls, DE) by using
selected ion monitoring of masses of 336 and 342 for
unlabelled and labelled phenylalanine, respectively. Enrich-
ment was corrected for the natural presence of the 13C
isotope. The tissue protein pellets were washed three times
with 2% perchloric acid, vacuum-dried overnight, and hydro-
lysed in 6M HCL at 120°C for 15–18 h. The hydrolysed protein
fraction was dried under a nitrogen stream while heated to
120°C before adding 50% acetic acid solution and passing the
hydrolysed protein over a Dowex exchange resin (AG 50W-
X8, 100–200 mesh hydrogen form; Biorad, Hercules, CA) by
using 2 M NH4OH. The eluate was collected for the
measurement of L-[ring-13C6]phenylalanine enrichment in
the samples. L-[ring-13C6]phenylalanine was derivatized to its
N(O,S)-ethoxycarbonyl ethyl esters. Thereafter, the ratios of
labelled to unlabelled derivatives were determined in quadru-
plicates by gas chromatography combustion isotope ratio
mass spectrometry (MAT 252; Finnigan, Bemen, Germany).
Standard regression curves were applied to assess the linearity
of the mass spectrometer and to control for loss of tracer.
Calculations
Protein synthesis rates were calculated as FSR, expressed as
%/h, using tissue and plasma L-[ring-13C6]phenylalanine
enrichments. The FSR was calculated using the standard
precursor-product equation:
FSR %=hð Þ ¼ Ep2  Ep1
Eprecursort100%:
Ep2 and Ep1 are the protein-bound enrichments measured
in the second biopsy (or only biopsy in the case of tumour
tissue12) (t = 2) and basal mixed plasma proteins (t = 0), re-
spectively (single biopsy approach). Eprecursor indicates the
average plasma free L-[ring-13C6]phenylalanine enrichment,
and t indicates the tracer incorporation time. For muscle
and liver tissue, FSRs were also calculated using the two
successive biopsy samples (successive biopsy approach). In
this case, Ep1 was the protein-bound enrichment measured
in the first biopsy (t = 1).
Although theoretically the ideal precursor pool for FSR
calculations would be the intracellular free-phenylalanine
enrichment, the average plasma phenylalanine enrichment
was chosen as preferred precursor pool because it is calcu-
lated over the entire tracer incorporation period, whereas
the intracellular free-phenylalanine enrichment can only be
assessed at the time of biopsy. For comparing both methods,
FSRs were also calculated by using the tissue-free phenylala-
nine enrichments as Eprecursor measured in the supernatant
of each processed biopsy. Comparing the calculation
methods using plasma and tissue free-tracer enrichments as
the precursor pool, we found an almost linear relationship
between the methods for both non-tumour pancreas
(R2 = 0.99) and tumorous pancreas (R2 = 0.87; data not
shown).
Statistical analyses
Data were analysed using IBM SPSS 23 for Microsoft
Windows®. All data are presented as mean and standard
error of mean. Phenylalanine enrichments are expressed in
mole per cent excess. Differences among tissues were
analysed using the Wilcoxon signed-rank test. Differences in
plasma enrichments over time were analysed using Friedman
ANOVA. A P-value of <0.05 was considered significant.
Results
From the eight enrolled patients with cancer of the pancre-
atic head (Table 1), six patients underwent PPPD and two pa-
tients had palliative double bypass surgery without
pancreatic resection. None of the patients had a history of
systemic steroid or anti-diabetic drug use within a year prior
to surgery. Skeletal muscle and liver biopsies were taken from
all eight patients without any complications. In the six pa-
tients receiving PPPD, healthy and tumour tissue from the
pancreas were also obtained. In all patients, a plasma
L-[ring-13C6]phenylalanine isotopic steady state was reached
within 2 h after starting the tracer infusion, with plasma
L-[ring-13C6]phenylalanine concentrations remaining stable
throughout surgery (Figure 2).
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Post-absorptive skeletal muscle protein synthesis rates
averaged 0.035 ± 0.005%/h, with rates ranging from 0.019 to
0.044%/h. Calculations using the successive biopsy approach
resulted in similar muscle protein synthesis rates
(0.039 ± 0.025%/h; P = 0.575). Quantification of the organ pro-
tein synthesis rates demonstrated much higher rates in organs
compared with skeletal muscle (Figure 3). In comparison with
skeletal muscle, protein synthesis rates in liver and pancreas
were 13-fold and 20-fold higher, respectively, with mean
values of 0.448 ± 0.043%/h (P = 0.012) and 0.694 ± 0.228%/h
(P = 0.028). Liver protein synthesis rates were significantly
lower when calculated using the successive biopsy approach
(0.310 ± 0.055%/h; P = 0.012), indicating a possible inhibitory
effect on protein synthesis during surgery.
Compared with healthy pancreas and liver tissue, samples
from pancreatic tumours had up to 2.6-fold lower protein
synthesis rates (0.268 ± 0.053%/h; P = 0.028; Figure 3).
Histological examination confirmed the presence of tumour
tissue in all (n = 6) tumour biopsies (Figure 4).
Discussion
In this study, we demonstrated that organ and tumour
protein synthesis rates are much higher than muscle protein
synthesis rates, with liver and pancreas tissue protein synthe-
sis rates exceeding tumour protein synthesis rates.
Although there are no studies that have compared human
muscle and organ tissue FSRs, the observed liver protein
synthesis rates are in line with liver protein synthesis rates of
0.32%/h13 and 0.62%/h14 reported previously in cancer pa-
tients using a 15N-glycine tracer. Heys and colleagues reported
even higher liver protein synthesis rates (0.96%/h),15 but this
finding is likely attributable to the flooding-dose technique
used, which may have led to an overestimation of FSR due to
the limited time frame of the experiment (<90 min).16 Liver
FSRs of the current study translate into turnover rates of
11 ± 1% per day, implying that liver tissue is highly dynamic.
These data are important in the context of liver regeneration
after partial hepatectomy, where regrowth of the resected tis-
sue has been observed at a rate of 0.8%of original liver volume
per day.17 In the current patient cohort, the elevated CRP,
IL-1β, and IL-6 levels suggest an (ongoing) acute phase re-
sponse, which could be partly driving the high liver FSRs. How-
ever, although liver protein synthesis rates of secreted acute
phase proteins are elevated in patients with high CRP,18
Fearon et al. demonstrated that fixed hepatic protein synthe-
sis is actually reduced in patients with colorectal liver metasta-
ses and systemic inflammation when compared with
non-oncologic controls.13 However, as liver metastases could
influence liver protein metabolism, future studies comparing
liver FSRs in metastases-free cancer patients with and without
ongoing acute phase response are warranted. Interestingly,
we found that liver protein synthesis rates were significantly
lower when calculated using the successive biopsy approach.
This may indicate a possible inhibitory effect of anaesthesia
and/or surgery on liver tissue protein synthesis. The successive
biopsy approach only uses the incorporation time during
surgery (and anaesthesia), while the single biopsy approach
uses both the periods before and during surgery to calculate
the tracer incorporation. Therefore, effects of surgery and
anaesthesia might be more noticeable in the successive biopsy
approach. In contrast, skeletal muscle protein synthesis rates
did not seem to be affected by anaesthesia as FSRs assessed
by single vs. successive biopsy approaches were not different
(see earlier discussion) and were consistent with those
reported previously by our laboratory12 and the vast amount
of published literature as shown in a systematic review.3 This
shows that stable isotope tracer infusion studies requiring
Figure 2 Plasma L-[ring-13C6]phenylalanine enrichments prior to and during surgery. Plasma phenylalanine enrichments remained stable throughout
surgery (P = 0.325, Friedman ANOVA) for all patients. Values are displayed as mean + standard error of the mean. MPE, mole per cent excess.
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Figure 3 Muscle, organ, and tumour tissue protein synthesis rates. Liver and pancreas protein synthesis rates were 13-fold and 20-fold higher than
those observed in skeletal muscle (*P = 0.012 and *P = 0.028, respectively, Wilcoxon signed-rank). Protein synthesis rates in pancreatic tumour tissue
were 2.5-fold and 1.6-folder lower, respectively, compared with those of the surrounding healthy pancreas and liver (*P = 0.028 and *P = 0.046, re-
spectively, Wilcoxon signed-rank). Data are presented as mean ± standard error of the mean. FSR, fractional synthetic rate.
Figure 4 Pancreatic tumour biopsy. (A) The pancreas head (arrow) is visible during pancreatic surgery. (B) The pancreas specimen is incised by the
pathologist revealing the pancreatic tumour (arrow). (C) Tumour containing tissue slice. (D) Frozen section of the tissue slice confirming the presence
of adenocarcinoma (arrows) (haematoxylin/eosin staining).
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steady state conditions are feasible even during such complex
abdominal surgery.
The high protein synthesis rates we observed in healthy
pancreas are consistent with the pronounced secretory
protein production by acinar cells.19 Pancreatic tumour
protein synthesis rates were more than 2.5-fold lower
compared with healthy pancreas and liver tissue, in contrast
to earlier findings that found relatively high tumour protein
synthesis rates.14 Ductal pancreatic adenocarcinomas consist
of epithelial tumour cells and stromal tissue that are not
specialized in protein secretion. Considering the small size of
pancreatic tumours (~2 cm in diameter20) and their relatively
low protein synthesis rates as observed here, pancreatic tu-
mours are unlikely to contribute substantially to whole-body
protein metabolism and are, therefore, unlikely a major driver
of protein loss in wasting disorders such as cancer cachexia.
However, tumour protein synthesis rates of 0.268 ± 0.053%/
h corresponding to 6 ± 1% per day could theoretically enable
a tumour to double in size within weeks, eventually leading
to a mass that could affect whole-body protein synthesis.
The fact that this does not occur in the majority of pancreatic
cancer patients further supports that protein breakdown
rates in tumours are (more) important for regulating (and
restricting) tumour growth, which is in line with previous
observations in rats.6 Although we did not aim to assess pro-
tein breakdown rates within our study design, the fact that
pancreatic tumours grow in size over time implies that tumour
protein breakdown rates do not exceed tumour tissue protein
synthesis rates.
It should be noted that although by itself the tumour FSR
might not influence whole-body protein metabolism directly,
the specific proteins produced by the tumour may represent
mediators altering whole-body protein metabolism. Many
tumours are capable of producing cytokines like IL-1β, IL-6,
and TNF-α, which can drive systemic inflammation and, as
such, contribute to muscle wasting.21 This might be a possible
explanation for the elevated levels of IL-1β and IL-6 in some
patients in the present study. Several potential mediators of
cancer cachexia produced by the tumour such as
proteolysis-inducing factor22 have been identified before,
although their significance on stimulating protein breakdown
in vivo in humans remains uncertain. Assessing synthesis
rates of specific proteins could provide much more insight
in the role of tumour protein synthesis in (muscle) wasting.
This is the first study to use contemporary isotope tracer
methodology to determine protein synthesis rates across
muscle, organ, and tumour tissues in vivo in humans. Two
earlier in vivo studies in colon and breast cancer patients
found relatively high tumour protein synthesis rates
compared with liver tissue.23,24 Potential explanations for
the differences between our study and previous studies could
be the advances in tracer methodology in recent years. Mass
spectrometry resolving power has substantially improved,
and we used a continuous tracer infusion instead of a
flooding dose. Furthermore, biopsy sampling differences
may account for different results. Earlier high protein synthe-
sis rates reported for tumour tissue may have inadvertently
included healthy tissue.14,23,24 Generally, tumour biopsies
are taken from the edge of the tumour or by needle biopsy.
This way, healthy tissue is easily mistaken for tumour tissue,
especially in case of oedema or inflammation around the
tumour. In our optimized tumour resection technique, we
took a transverse section of the entire tumour that was iden-
tified by the pathologist macroscopically and confirmed mi-
croscopically thereafter, ensuring the sample analysed
contained exclusively tumour tissue instead of healthy tissue.
In conclusion, pancreatic tumour protein synthesis rates
are relatively low compared with protein synthesis rates in
healthy tissue surrounding the tumour. Organ tissue protein
synthesis rates by far exceed muscle protein synthesis rates
and, as such, have the potential to strongly influence
whole-body protein metabolism in both health and disease.
Therefore, the focus of protein metabolism research should
be expanded to include both muscle and organ tissues in or-
der to fully explore the contribution of organ protein synthe-
sis rates in wasting disorders including various types of
cancers, inflammatory bowel disease, and chronic infections.
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